Drug-Induced Fatty Liver Disease

Drug-induced fatty liver disease (DIFLD) covers a group of adverse drug reactions whose prevalence accounts for about 10% of all adverse reactions. The aim of this review was to analyse and summarise data on medicines that can potentially lead to the development of DIFLD, as well as on the pathophysiological mechanisms of its development, methods of its diagnosis, treatment, and prevention. The analysis of scientifi c literature showed that most often this complication occurred following the use of amiodarone, methotrexate, tamoxifen, valproic acid, and some other medicines. It was demonstrated that the main risk factors for developing DIFLD are comorbidity/polymorbidity and mitochondrial dysfunction. Due to the lack of pathognomonic clinical manifestations of DIFLD the best approach to making diagnosis is to obtain a thorough medical history, including medication history, to use RUCAM and Naranjo scales, to analyse a number of blood chemistry parameters (alanine transaminase, aspartate transaminase, bilirubin, alkaline phosphatase), and, if necessary, to perform liver biopsy. Whenever DIFLD is observed in a patient, it is necessary, if possible, to discontinue the use of the medicine that caused the adverse reaction, or to lower its dose and to exclude the factors that may potentially aff ect the patient’s condition. The following measures will help healthcare professionals to prevent and detect DIFLD in a timely manner: observing the requirements of the patient information leafl et, taking into account any comorbidity and potential adverse drug interactions, as well as regular monitoring of the condition of patients taking medicines with known hepatotoxic eff ects.

drug-induced liver injury, drug-induced fatty liver disease, adverse drug reactions, comorbidity, polymorbidity, mitochondrial dysfunction

1. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66; quiz 967. https://doi.org/10.1038/ajg.2014.131

2. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–22. https://doi.org/10.1055/s-0034-1375953

3. Lazeb nik LB, Golovanova EV, Hlynova OV, Alekseenko SA, Aryamkina OL, Bakulin IG, et al. Medicinal liver damage in adults. Eksperimental’naia i klinicheskaia gastroenterologiia = Experimental & Clinical Gastroenterology. 2020;174(2):29–54 (In Russ.) https://doi.org/10.31146/1682-8658-ecg-174-2-29-54

4. Bueverov AO. Medicinal liver damage. RMZh = RMJ. 2012;(3):107 (In Russ.)

5. Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139(7):876–87. https://doi.org/10.5858/arpa.2014-0214-RA

6. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Druginduced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14. https://doi.org/10.1016/j.jhep.2015.04.016

7. Galimova SF. Drug-induced liver injuries (Part 1). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(3):38–48 (In Russ.)

8. Balasanyants GS. Hepatotoxic reactions and hepatoprotective therapy in tuberculosis control. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases. 2015;(8):48–53 (In Russ.)

9. Mordyk AV, Ivanova OG, Nagibina LA, Sitnikova SV, Marekhina OA. Drug-induced liver lesions and their management in the manifestations of tuberculosis. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases. 2015;(9):47–53 (In Russ.)

10. Ivanova DA. Drug-induced liver injury on the background of anti-tuberculosis chemotherapy: epidemiology, diagnostic approach. Meditsinskiy al’yans = Medical Alliance. 2015;(1):98–9 (In Russ.)

11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. https://doi.org/10.1016/j.jhep.2019.02.014

12. Malinowski SS, Riche DM. Chapter 38. Hepatic and cholestatic diseases. In: Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2018. P. 845–76.

13. Tulgaa L, Tserendash B, Ignatieva LP. Fatty liver as one of the actual problems of hepatology. Sibirskiy meditsinskiy zhurnal (Irkutsk) = Sibe rian Medical Journal (Irkutsk). 2005;(4):17–22 (In Russ.)

14. Miele L, Liguori A, Marrone G, Biolato M, Araneo C, Vaccaro FG, et al. Fatty liver and drugs: the two sides of the same coin. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):86–94.

15. Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905. https://doi.org/10.1155/2015/168905

16. Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789–806. https://doi.org/10.5604/16652681.1171749

17. Dash A, Figler RA, Sanyal AJ, Wamhoff BR. Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol. 2017;13(2):193– 204. https://doi.org/10.1080/17425255.2017.1246534

18. Breiden B, Sandhoff K. Emerging mechanisms of drug-induced phospholipidosis. Biol Chem. 2019;401(1):31–46. https://doi.org/10.1515/hsz-2019-0270

19. Ivashkin VT, Baranovsky AYu, Raikhelson KL, Palgova LK, Maevskaya MV, Kondrashina EA, et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):101–31 (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-1-101-131

20. Pavlik L, Regev A, Ardayfi o PA, Chalasani NP. Drug-Induced Steatosis and Steatohepatitis: The search for novel serum biomarkers among potential biomarkers for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Drug Saf. 2019;42(6):701– 11. https://doi.org/10.1007/s40264-018-00790-2

21. Yang L, Zhong X, Li Q, Zhang X, Wang Y, Yang K, et al. From the cover: potentiation of drug-induced phospholipidosis in vitro through PEGlyated graphene oxide as the nanocarrier. Toxicol Sci. 2017;156(1):39–53. https://doi.org/10.1093/toxsci/kfw233

22. Korenskaya EG, Paramonova OV. Drug-induced liver injury is one of the important problems in the comorbid patient. Consilium Medicum. 2019;21(8):78–83 (In Russ.) https://doi.org/10.26442/20751753.2019.8.190355

23. Pimanov SI, Makarenko EV. Idiosyncratic drug-induced liver injury: diagnosis and treatment. Meditsinskiy sovet = Medical Council. 2017;(5):100–7 (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-100-107

24. Aithal GP. Pharmacogenetic testing in idiosyncratic druginduced liver injury: current role in clinical practice. Liver Int. 2015;35(7):1801–8. https://doi.org/10.1111/liv.12836

25. Tsuda T, Tada H, Tanaka Y, Nishida N, Yoshida T, Sawada T, et al. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. J Med Case Rep. 2018;12(1):95. https://doi.org/10.1186/s13256-018-1629-8

26. Kum LC, Chan WW, Hui HH, Wong GW, Ho SS, Sanderson JE, et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. Clin Cardiol. 2006;29(7):295–9. https://doi.org/10.1002/clc.4960290705

27. Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4(9):1250–9. https://doi.org/10.1016/j.hrthm.2007.07.020

28. Huang CH, Lai YY, Kuo YJ, Yang SC, Chang YJ, Chang KK, et al. Amiodarone and risk of liver cirrhosis: a nationwide, population-based study. Ther Clin Risk Manag. 2019;15:103–12. https://doi.org/10.2147/TCRM.S174868

29. In brief: FDA warning on dronedarone (Multaq). Med Lett Drugs Ther. 2011;53(1359):17.

30. Kim TH, Kim YB, Cheong JY, Cho SW, Kim SS. Tamoxifeninduced non-alcoholic steatohepatitis cirrhosis. Soonchunhyang Med Sci. 2018;24(1):81–4. https://doi.org/10.15746/sms.18.014

31. Shimizu H, Shimizu T, Takahashi D, Asano T, Arai R, Takakuwa Y, et al. Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report. BMC Musculoskelet Disord. 2019;20(1):88. https://doi.org/10.1186/s12891-019-2468-5

32. Gayam V, Mandal AK, Khalid M, Shrestha B, Garlapati P, Khalid M. Valproic acid induced acute liver injury resulting in hepatic encephalopathy—a case report and literature review. J Community Hosp Intern Med Perspect. 2018;8(5):311–4. https://doi.org/10.1080/20009666.2018.1514933

33. Najafi N, Heidari R, Jamshidzadeh A, Fallahzadeh H, Omidi M, Abdoli N, et al. Valproic acid-induced hepatotoxicity and the protective role of thiol reductants. Trends in Pharmaceutical Sciences. 2017;3(2):63–70.

34. Trukhan DI. Role and location of L-carnitine in cytoprotection and correction of metabolic processes in patients with metabolic syndrome. Meditsinskiy sovet = Medical Council. 2017;(12):182–7 (In Russ.) https://doi.org/10.21518/2079-701X-2017-12-182-187

35. Neukam K, Mira JA, Collado A, Rivero-Juárez A, Monje-Agudo P, Ruiz-Morales J, et al. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: the HEPAVIR SEG-HEP Cohort. PLoS One. 2016;11(2):e0148104. https://doi.org/10.1371/journal.pone.0148104

36. Conway R, Carey JJ. Risk of liver disease in methotrexate treated patients. World J Hepatol. 2017;9(26):1092–100. https://doi.org/10.4254/wjh.v9.i26.1092